Highlights newsletter 1
This newsletter presents you the following key sessions:
1. Video-interview with Professor Martin Griesshammer about the 80-week follow-up data from the RESPONSE-2 trial:
efficacy and safety profile of ruxolitinib in adequately controlled polycythemia vera patients
2. The combination of ixazomib, lenalidomide and dexamethasone for patients with relapsed/refractory multiple
myeloma in real-world
3. FDG-PET after 2 cycles of eBEACOPP allows the reduction from therapy without loss of efficacy in advanced-
stage HL patients.
4. Bleeding or clotting in elderly patients with cancer-associated venous thromboembolism: which is worse?
5. Patients with relapsed/refractory B-cell malignancies treated with cerdulatinib, a dual Syk-JAK inhibitor, have
rapid tumor responses